Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Abstract The Alzheimer's Association's Research Roundtable met in May 2014 to explore
recent progress in developing biomarkers to improve understanding of disease …

At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β
(Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …

Alzheimer's disease (AD) is the most common cause of dementia and affects a large portion
of the elderly population worldwide. Currently, a diagnosis of AD depends on the clinical …

Alzheimer's disease (AD) characterization has progressed from being indexed using clinical
symptomatology followed by neuropathological examination at autopsy to in vivo signatures …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

Four fluid-based biomarkers have been developed into diagnostic tests for Alzheimer's
disease (AD) pathology: the ratio of 42 to 40 amino acid-long amyloid β, a marker of plaque …